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EXPERTISE - NO LONGER A SINE QUA NON FOR 
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Guidelines are traditionally scripted by a panel of experts who are intimately familiar with the 
topic in question. Practicing physicians inherently trust guideline authors and rarely ever question 
their expertise, especially when guidelines are endorsed by such venerable societies as the 
American College of Physicians (ACP) and the American Academy of Family Practitioners 
(AAFP) and are published in high impact journals such as the Annals of Internal Medicine. The 
more than 250,000 members of the ACP and AAFP have come to expect that any set of clinically 
meaningful guidelines has been put together by authors who were selected because of their 
outstanding skills and expertise pertaining to the topic in question. Thus, there is little if any 
reason to voice doubt as to the validity of published guidelines 
The Free Dictionary defines expertise as “special skills or knowledge acquired by a person 
through education, training, or experience.” For a physician unfamiliar with the experts, there are 
several simple ways to get a grasp on the quality and quantity of expertise:  
1. One can scrutinize the publication list of the experts, to assess how often they have been 
involved with the guideline topic. Any expert is expected to be well published in the 
specific area of the expertise.  
2. One may take into account an expert’s membership in professional organizations 
pertaining to the subject matter. Obviously, membership and participation in annual 
meetings demonstrates an ongoing interest in the guideline topic.  
3. One may examine whether the physician/scientist has been invited to serve on editorial 
boards of journals dealing with the topic in question.. Being a member of an editorial 




When one scrutinizes the authors of what is called the Joint National Committee (JNC) 8 (2), 
there is little doubt that most of them were indeed true experts, displaying “skills or knowledge 
acquired through education, training, or experience” to guide other physicians in detection, 
evaluation, and treatment of patients with hypertension. Many of these authors have extensively 
published on hypertensive cardiovascular disease, are members of professional societies and 
editorial boards of peer reviewed journals on hypertension (Table 1).   
 
Such is unfortunately not the case when canvassing the authors of the recent “Clinical Practice 
Guideline from the American College of Physicians and the American Academy of Family 
Physicians” pertaining to “Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or 
Older” (3). Table 1 compares the authors of JNC 8 with the authors of the ACP/AAFP Guidelines 
pertaining to publication record on hypertension, membership in professional societies and 
membership of editorial boards. The highly statistically significant results mostly are self-
explanatory.  In fact, as per PubMed, 3 of the 7 guideline authors have never authored an article 
on hypertension and 1 has coauthored a single study only. Moreover, not one of the authors of the 
ACP/AAFP Guideline is known to be a hypertension specialist certified by the American Society 
of Hypertension (ASH) or even a member of ASH or of the AHA Council for High Blood 
Pressure. In contrast, more than half of the JNC 8 authors are certified ASH specialists and even 
more are ASH members. No ACP/AAFP Guideline author is currently serving’on the editorial 
board of a journal dealing with hypertension such as Hypertension, Journal of Hypertension, 
American Journal of Hypertension etc., whereas the JNC 8 authors have a total of 17 editorial 
board memberships.   
In order, not to overlook any hypertension experts we, also examined the individuals who were 
listed serving on the ACP Clinical Guidelines Committee from initiation of the project until its 
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approval. If anything, their records of the same expertise criteria is even inferior to those of the 
authors. One can of course argue that hypertension is a common disorder and those individuals 
listed as serving on the ACP Clinical Guidelines who are practicing physicians, have treated and 
continue to treat hypertensive patients.  However, the mere fact that you know how and when to 
prescribe hydrochlorothiazide does not make you an expert in hypertensive cardiovascular 
disease. 
On a somewhat positive note, the authors clearly have extensive know-how as to formalities 
regarding composition of guidelines and are aware of pertinent rules and regulations. Also, 
compared with the JNC 8 authors, the ACP/AAFP Guideline authors have a much shorter list of 
conflicts of interest. By no means are we suggesting that such authorship should consist of 
experts only, but at a minimum, experts should be part of it or at least extensively consulted. The 
complete absence of individuals with experience in hypertensive cardiovascular disease makes 
the ACP/AAFP Guidelines unacceptable to practicing physicians. 
To list various deficiencies in the ACP/AAFP Guidelines is beyond the scope of this 
commentary. Briefly, the authors make very similar recommendations as JNC 8, which depended 
on evidence that was strong in itself, but not truly relevant to the guideline's most vital question: 
What is the optimal blood pressure treatment target in hypertensive patients aged 60 or over?   
Importantly new outcomes evidence and analyses available since JNC 8 was published, appear to 
have been discounted by the ACP/AAFP Guideline authors. Of concern is that SPRINT-Elderly 
data or any of the subsequent analyses have been ignored. Clearly these findings are seminal to 
the above question (4,5).  
Of note, the meta-analysis (6) on which the ACP/AAFP Guidelines are based, although 
supposedly dealing with adults aged 60 years or older, included randomized trials of patients with 
a mean age of at least 60 years. This means that this meta-analysis (and the resulting guidelines) 
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were based on findings from numerous patients who were below that age limit. In addition, as 
pointed out by Bangalore (S. Bangalore, personal communication), one of the issues with the 
underlying meta analysis pertains to the problematic terminology of "intensive" and "standard". 
The "intensive" arm of ADVANCE (Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation) (~134 mm Hg) achieved similar BP control 
as the "standard" arm of ACCORD (The Action to Control Cardiovascular Risk in Diabetes 
Study Group) or SPRINT  (Systolic Blood Pressure Intervention Trial) (133 mm Hg) and 
therefore combining this in a meta analysis is inappropriate.  
 
 
Regarding safety, the ACP/AAFP Guidelines fail to identify angioedema as a rare but potentially 
fatal adverse event of angiotensin converting enzyme inhibitors (7, 8). African American patients 
are at a particularly high risk of angioedema with this drug class (8, 9, 10). Since the angioedema 
may manifest itself months after initiation of therapy, not uncommonly neither patient nor 
physician connect the dots between the antihypertensive medication and periodic swelling of lips, 
tongue and larynx. Not to even list angioedema as an adverse event is a most troubling omission.  
We are not privileged to know who selected the authors for the ACP/AAFP Guidelines, nor do 
we have access to selection criteria. In most US and international guidelines (2, 11, 12) selection 
has been expertise based. However, as illustrated by ACP/AAFP Guidelines, expertise no longer 
seems to be a prerequisite, or sine qua non, for authoring guidelines for practicing physicians. If 
there were selection criteria for the authors of these hypertension guidelines, they must have been 
other than “special skills or knowledge acquired by a person through education, training, or 
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Table 1: Comparison of publications, Society of Hypertension certification and membership, and 
Editorial Board Membership (as per 01/2017) 












No. of authors=17 
39 (5.5-121) 8 12 17 
ACP/AAFP 
No. of authors=6 
0.5 (0-2.5) 0 0 0 
Associated 
members 
ACP/AAFP No. = 
28 
0 (0-0.75) 0 0 0 
2013 ESC/ESH 
No. of authors=25 
98 (40.5-197) 17 18 23 
 
* Median (interquartile range) 
† http://www.ash-us.org/Physician-Directory.aspx and 
http://www.eshonline.org/communities/hypertension-specialist/directory-of-specialists/, 
respectively 
‡ American Society of Hypertension (ASH) and European Society of Hypertension (ESH), 
respectively  
§  Hypertension, Journal of Hypertension, American Journal of Hypertension, Journal of the 
American Society of Hypertension, Journal of Human Hypertension, and Journal of Clinical 
Hypertension 
 
